Radiofrequency ablation (RFA) is a safe and effective treatment in patients with unresectable liver malignancies.
However, there is little information on its optimal approach, the feasibility, clinical outcome, and efficacy.
In this study, researchers treated 23 consecutive patients with unresectable hepatic malignancies using RFA.
The team’s findings are published in the January issue of Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.
The team performed RFA percutaneously in 5 patients, via laparotomy in 9, and via laparoscopy in 9. Overall, there was no mortality or intraoperative complications.
The researchers determined that mean blood loss was 13 ml versus 421 ml for the laparoscopy and laparotomy groups, respectively. Mean hospital stay was 5.7 days versus 11.2 days, respectively.
|New hepatic tumors developed in 7 patients.|
|Surgical Laparoscopy, Endoscopy & Percutaneous Techniques|
Postoperative complications occurred in 1 patient after laparoscopic RFA, and in 3 following RFA via laparotomy.
The team found that after a median follow-up of 12.2 months, local recurrence occurred in 2 patients. New hepatic tumors developed in 7.
Dr Baki Topal’s team concluded, “Laparoscopic RFA is a safe and feasible treatment modality to achieve tumor destruction in selected patients with unresectable hepatic malignancies”.